Metrics to compare | 9877 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship9877PeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.5x | 19.4x | −0.4x | |
PEG Ratio | 0.20 | 0.04 | 0.00 | |
Price/Book | 3.3x | 2.4x | 2.6x | |
Price / LTM Sales | 28.4x | 4.0x | 3.1x | |
Upside (Analyst Target) | - | 49.1% | 47.5% | |
Fair Value Upside | Unlock | 22.6% | 5.9% | Unlock |
Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of interventional products for the treatment of structural heart diseases in the People’s Republic of China. It offers LuX-Valve and LuX-Valve Plus, a transcatheter tricuspid valve replacement (TTVR) product for the treatment of severe tricuspid regurgitation and high surgical risk; Ken-Valve, a TRVR system for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops JensClip, a clip-based transcatheter mitral valve intervention (TMVR) repair system to treat patients with severe mitral regurgitation; JensRelive, a TMVR system to treat patients with severe mitral regurgitation and replace dysfunctional primary mitral valves without undergoing routine thoracotomy surgery; and SimuLock, a bionics left atrial appendage occluder system for cardiogenic stroke prevention. In addition, it offers platform technologies/accessories comprising introducer kit, JeniGal anti-calcification technology, dry-tissue technology and polymer leaflet technology; and engages in consulting and investment activities. The company was incorporated in 2011 and is headquartered in Ningbo, the People’s Republic of China.